Valuation: Nanjing Gaoke Company Limited

Capitalization 13.44B 1.85B 1.78B 1.68B 1.5B 2.65B 160B 2.95B 20.34B 7.55B 65.88B 6.94B 6.79B 287B P/E ratio 2022
4.76x
P/E ratio 2023 6.7x
Enterprise value 20B 2.75B 2.64B 2.49B 2.23B 3.95B 238B 4.39B 30.26B 11.23B 98B 10.32B 10.1B 428B EV / Sales 2022
3.44x
EV / Sales 2023 3.59x
Free-Float
55.21%
Yield 2022
6.35%
Yield 2023 4.64%
More valuation ratios * Estimated data
Dynamic Chart
Nanjing Gaoke Q3 Profit Rises 59%, Revenue Falls 68% 24-10-24 MT
Nanjing Gaoke Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2024 24-10-23 CI
Nanjing Gaoke's H1 Profit Slip 12%, Operating Income Drops 62%; Shares Up 5% 24-08-30 MT
Nanjing Gaoke Company Limited Reports Earnings Results for the Half Year Ended June 30, 2024 24-08-29 CI
Wuxi Lingpao Microelectronics Co., Ltd. announced that it has received CNY 100 million in funding from Nanjing Gaoke Company Limited, Welight Capital, Yi Ling Capital Management Co., Ltd., Shenzhen Qianhai Pengchen Investment Management Co., Ltd., BlueRun Investment Consulting Co., Ltd., Wuxi Xinshang Investment Co., Ltd., and other investors 24-07-12 CI
Wuxi Lingpao Microelectronics Co., Ltd. announced that it has received funding from Nanjing Gaoke Company Limited, Yi Ling Capital Management Co., Ltd., Shenzhen Qianhai Pengchen Investment Management Co., Ltd., BlueRun Investment Consulting Co., Ltd., Wuxi Xinshang Investment Co., Ltd. 24-07-12 CI
Nanjing Gaoke's Equity Investment Project Rimag Group Lists on Hong Kong Bourse 24-06-06 MT
Nanjing Gaoke Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023 24-04-26 CI
Nanjing Gaoke Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 24-04-25 CI
Nanjing Gaoke's Q4 Contracted Sales Drop 69% 24-01-26 MT
Nanjing Gaoke Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2023 23-10-30 CI
Nanjing Gaoke Raises 500 Million Yuan From 180-Day Bond Sale 23-10-19 MT
Nanjing Gaoke Company Limited Reports Earnings Results for the Half Year Ended June 30, 2023 23-08-30 CI
More news
1 week+1.93%
Current month-4.89%
1 month-2.89%
3 months+9.00%
6 months+26.98%
Current year-4.89%
More quotes
1 week
7.23
Extreme 7.23
7.51
1 month
6.96
Extreme 6.96
7.95
Current year
6.96
Extreme 6.96
7.83
1 year
5.43
Extreme 5.43
8.77
3 years
5.43
Extreme 5.43
8.77
5 years
5.43
Extreme 5.43
8.98
10 years
4.14
Extreme 4.1429
13.04
More quotes
Director TitleAgeSince
Director of Finance/CFO 50 2016-12-21
Director of Finance/CFO 54 2009-10-31
Investor Relations Contact - -
Manager TitleAgeSince
Chairman 62 2003-05-31
Director/Board Member 54 2019-04-09
Director/Board Member 62 2016-12-21
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
0.00%+1.93%+24.20%+7.32%1.76B
-0.56%-0.49%+4.80%-39.83%24.4B
+0.95%+0.95%+10.53%+3.53%10.62B
+7.45%+6.51%-21.79%-65.99%11.3B
-0.76%-0.65%+5.46%-33.53%9.5B
0.00%0.00%-7.08%-49.62%6.5B
-1.52%-1.64%+3.13%-33.12%5.95B
+0.12%+0.62%-6.58%-57.64%5.96B
-0.66%+0.99%-1.69%-2.14%4.07B
-1.90%-0.73%+10.58%-13.68%3.86B
Average +0.31%+2.49%+2.16%-28.47% 8.39B
Weighted average by Cap. +0.66%+3.37%+0.53%-34.68%
See all sector performances

Financials

2022 2023
Net sales 4.49B 618M 594M 560M 501M 886M 53.41B 985M 6.79B 2.52B 22B 2.32B 2.27B 95.98B 4.73B 651M 626M 590M 528M 934M 56.3B 1.04B 7.16B 2.66B 23.19B 2.44B 2.39B 101B
Net income 2.4B 330M 318M 300M 268M 474M 28.58B 527M 3.64B 1.35B 11.77B 1.24B 1.21B 51.35B 1.56B 215M 206M 195M 174M 308M 18.56B 342M 2.36B 876M 7.64B 805M 788M 33.35B
Net Debt 3.99B 549M 527M 497M 445M 787M 47.45B 875M 6.04B 2.24B 19.55B 2.06B 2.02B 85.27B 6.56B 902M 867M 818M 732M 1.29B 77.98B 1.44B 9.92B 3.68B 32.12B 3.38B 3.31B 140B
More financial data * Estimated data
Logo Nanjing Gaoke Company Limited
NANJING GAOKE COMPANY LIMITED is a China-based company, principally engaged in real estate and municipal businesses, medical health business and equity investment business. Its real estate business includes residential development, commercial operations and property management, among others. Its medical health business includes the research and development, manufacture and sales of pharmaceuticals. The Company operates its businesses primarily in Nanjing, Jiangsu province, China.
Employees
508
More about the company
Date Price Change Volume
25-01-21 7.390 ¥ 0.00% 13,473,720
25-01-20 7.390 ¥ 0.00% 12,079,820
25-01-17 7.390 ¥ +1.23% 14,036,470
25-01-16 7.300 ¥ 0.00% 14,581,920
25-01-15 7.300 ¥ +0.69% 16,236,150

End-of-day quote Shanghai S.E., January 20, 2025

More quotes
  1. Stock Market
  2. Equities
  3. 600064 Stock